ID: ALA4107219

Max Phase: Preclinical

Molecular Formula: C10H19NO4

Molecular Weight: 217.26

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CC1CC1

Standard InChI:  InChI=1S/C10H19NO4/c12-5-7-9(14)10(15)8(13)4-11(7)3-6-1-2-6/h6-10,12-15H,1-5H2/t7-,8+,9-,10-/m1/s1

Standard InChI Key:  KWBAIPASFIBUNH-UTINFBMNSA-N

Associated Targets(non-human)

Lysosomal alpha-glucosidase 58 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 217.26Molecular Weight (Monoisotopic): 217.1314AlogP: -1.84#Rotatable Bonds: 3
Polar Surface Area: 84.16Molecular Species: NEUTRALHBA: 5HBD: 4
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.90CX Basic pKa: 8.49CX LogP: -1.72CX LogD: -2.84
Aromatic Rings: 0Heavy Atoms: 15QED Weighted: 0.45Np Likeness Score: 1.16

References

1.  (2015)  Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives, 

Source

Source(1):